Clinical Trial Update: Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations [Phase 2]

View source ↗

Summary

This Phase 2 trial update evaluates chemotherapy combined with either panitumumab or bevacizumab for inoperable cholangiocarcinoma lacking KRAS mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Panitumumab (panitumumab)

Snippet

Sponsor: Vejle Hospital | Conditions: Cholangiocarcinoma | Phase 2 | Status: COMPLETED